Aurora A Is Critical for Survival in HPV-Transformed Cervical Cancer

Brian Gabrielli1, Fawzi Bokhari1, Max V. Ranalli1, Zay Yar Oo1, Alexander J. Stevenson1, Weili Wang1, Melanie Murrell2, Mushfiq Shaikh2, Sora Fallaha2, Daniel Clarke2, Madison Kelly2, Karin Sedelies3, Melinda Christensen3, Sara McKee1, Graham Leggatt1, Paul Leo1, Dubravka Skalamera1, H. Peter Soyer4, Thomas J. Gonda1, and Nigel A.J. McMillan2

Abstract

Human papillomavirus (HPV) is the causative agent in cervical cancer. HPV oncoproteins are major drivers of the transformed phenotype, and the cancers remain addicted to these oncoproteins. A screen of the human kinome has identified inhibition of Aurora kinase A (AURKA) as being synthetically lethal on the background of HPV E7 expression. The investigational AURKA inhibitor MLN8237/Alisertib selectively promoted apoptosis in the HPV cancers. The apoptosis was driven by an extended mitotic delay in the Alisertib-treated HPV E7–expressing cells. This had the effect of reducing Mcl-1 levels, which is destabilized in mitosis, and increasing BIM levels, normally destabilized by Aurora A in mitosis. Overexpression of Mcl-1 reduced sensitivity to the drug.

Introduction

Human papillomavirus (HPV) has been identified as the definitive agent in cancers of the cervix, penis, vulva, vagina, anus, skin, eye, and head and neck, and is responsible for more than 610,000 deaths, 5% of the total cancer burden worldwide (1). The papillomaviruses are small, double-stranded DNA viruses belonging to the family Papillomaviridae. High-risk HPVs have been identified as the causative agent in 99.7% cervical cancers (2), have been detected in more than 50% of other anogenital cancers, and in more than 70% of cancers of the oropharynx (3, 4). The most prevalent high-risk HPV types are HPV-16 and HPV-18, which account for approximately 70% of HPV cancer cases, with another 10 high-risk types making up the other 30% (5).

Although HPV vaccines are available and highly effective (reviewed in ref. 6), they are clearly most useful if given before viral exposure. Even with the advent of vaccines, cervical cancer will remain a serious health issue in unvaccinated and under-vaccinated women (7). The use of more targeted approaches is now beginning to improve outcomes in other cancers but no such therapy for HPV-driven cancers is in the clinic. Indeed, chemotherapy is still the primary treatment modality and there has been little improvement in 5-year outcomes (8).

High-risk HPV promotes cancer via the actions of the E6 and E7 oncogenes. The E6 gene product binds to the p53 tumor-suppressor protein and targets it for ubiquitin-mediated degradation (9). E6 also blocks senescence by stimulating telomerase activity as well as an increasing number of other proteins (10). The E7 protein also has a range of targets, including the retinoblastoma protein (pRb) family, the MuvB complex, and directly drives genomic instability (10, 11). Therefore, the overexpression of E6 and E7 allows uncontrolled cell growth and increased genomic instability, which promotes transformation and carcinogenesis. This process occurs over an extended timeframe (up to 20 years) due to the fact that E6/E7 alone are not sufficient to drive cancer; secondary mutational events also contribute (12), thus making specific treatment difficult as each HPV cancer has a different spectrum of mutations.

The one consistent feature of cervical cancers is the continued dependence on HPV E6 and E7 expression. Depletion of E6/E7 is sufficient to drive even long established cell lines into either
senescence or apoptosis, depending on the level of depletion achieved (13). This continuing dependence on E6/E7 suggests that drugs that targeting E6/E7 are also likely to be selective for HPV-transformed cancers. We have undertaken a functional genomics screen to identify genes involved in E6/E7-driven dependency that are essential to the survival of HPV-driven cancers. Here, we show for the first time that targeting of the Aurora A kinase using the inhibitor Alisertib results in a profound inhibition of HPV-driven tumor growth, and that this selectivity is through targeting an interaction between Aurora A and HPV E7 in mitosis.

Materials and Methods

Cell culture
All cervical cancer cell lines were originally obtained from the ATCC except for C33A. Cervical cancer cell lines (HeLa, CaSki, ME-180, SiHa, C33A, HT3, and C33A-HPV16-E7) were maintained in complete DMEM (GIBCO; Invitrogen) supplemented with 10% serum supreme (Biowhittaker; Lonza), 1 mmol/L sodium pyruvate (GIBCO) and 2 mmol/L L-glutamine (GIBCO) at 37°C and 5% CO2. Squamous cell carcinoma cell lines were kindly given by Associate Professor Nicholas Saunders (The University of Queensland Diamantina Institute, Brisbane, Australia) and were cultured in DMEM/F12 (1:1; GIBCO) containing 10% serum supreme (Lonza) at 37°C and 5% CO2. All cell lines were tested and free of Mycoplasma and authenticated with short tandem repeat fingerprinting at the time of use. SCC25 cells were transduced with lentivirus-expressing HPV18 E7 or empty vector as described previously (14). The vector places the HPV18 E7 5’ of an IRES GFP resulting in GFP coexpression at a level, which is an indicator of the level of E7 expression. qPCR analysis of relative E7 gene expression was undertaken using ΔΔCt analysis and β-actin as the housekeeper.

siRNA screening
Detailed methods for the siRNA screening are provided in Supplementary Material.

Flow cytometry
All tested cells were exposed to final concentrations of 5 μmol/L Alisertib, 5 μmol/L ZM447439, or DMSO (vehicle) for 24, 48, or 72 hours. Cells were analyzed for DNA content by flow cytometry using BD FACS-Canto II (BD Biosciences) and data analyzed with FlowJo software (FlowJo Co.) as described previously (15).

Time-lapse microscopy
Cells were either treated with 5 μmol/L Alisertib or DMSO (vehicle), then followed by time-lapse microscopy using a Zeiss Axiosvert 200M Cell Observer microscope equipped with an incubation chamber at 37°C and 5% CO2. Images were captured at 20 minute intervals with a minimum of 150 cells per condition per cell line analyzed as described previously (15). Time in mitosis and exit from mitosis was observed and assessed for successful cellular division, failure of cytokinesis, or cell death.

Immunoblotting
Cells were lysed and immunoblotted as described previously using chemiluminescence detection imaged with a CCD camera (15). Band intensities were quantitated using ImageJ software. Antibodies to Bim, Bcl-2, PARP, cleaved caspase-3 (Cell Signalling Technology), Aurora A and Aurora B (Becton-Dickinson), Bcl-XL (AbCam), Mcl-1 (Millipore), and α-tubulin (Sigma-Aldrich) were purchased from the indicated suppliers.

Mouse xenograft models
Mice (6-weeks-old female Nude; ARC) were inoculated s.c. in the right flank with 1 × 106 cells in Matrigel. For each cell line, 6 mice were used for the treatment with Alisertib and 6 for the vehicle control only. When tumors were palpable (~1 week following injection) 100 μL oral gavage of 30 mg/kg Alisertib was administered daily for 10 consecutive days. Mice were then scored daily by scoring any tumor regrowth or until culled. All animal studies were approved by University of Queensland Animal Ethics.

K14E7 transgenic mouse grafting experiments
Groups of 7 mice, with well-healed (up to 5 months) grafts of either wild-type or K14E7 skin were treated with or without two cycles of Alisertib as for the xenograft experiments. At between 2 and 10 days after the final cycle, mice were sacrificed and grafts harvested for immunohistochemical staining. Formalin-fixed, paraffin-embedded samples were either immunostained for cleaved caspase-3 (Cell Signaling Technology) or mast cells using toluidine blue, pH 1. The number of cells stained was visually assessed by microscopy.

Immunofluorescence
Cells were cultured on poly-L-lysine coated glass coverslips with vehicle (DMSO) or 5 μmol/L Alisertib for 24 or 48 hours. Coverslips were fixed with −20°C methanol and stored at −20°C until processing. Coverslips were stained for microtubules and DNA as described previously (16).

qPCR
Extract of RNA, cDNA generation, and qPCR were carried out as described previously (17).

Results

siRNA library screen and target selection
To discover synthetic lethal interactions with the HPV onco-genes E7 and E6 in cervical cancers, we undertook an siRNA library kinome screen using the Dharnacoon human siGENOME siRNA library for Protein Kinases (targeting 779 genes). The primary screen used CaSki (cervical cancer HPV16), and C33A (cervical cancer non-HPV) cell lines. Data were normalized using Z-score transformation for each assay and cell line, and genes sorted by Z-score on CaSki viability. Using the parameters of viability, cytotoxicity, and cell number, we identified genes that when depleted were selectively lethal to the HPV-positive CaSki cell line compared with the HPV-negative C33A cells (Fig. 1A; full data presented in Supplementary Table S1). This was visualized using hierarchical clustering and Principle Components Analysis (details of the analysis are provided in Supplementary Fig. S1). We identified a group of genes whose knockdown result in reduced viability in all cells, including PLK1, WEE1, and COPB2, which were excluded from further analysis. From this primary screen, we identified a set of 54 genes for secondary screening using the OnTarget Plus siRNA Smart Pools that have reduced off-target effects due to their modified passenger strand and >90% have different target sites...
The secondary screen siRNAs were applied to a larger panel of cell lines including HeLa (HPV18), SiHa (HPV16), and HaCaT (HPV negative) cells using the viability, cytotoxicity, and cell count assay parameters. From the secondary screen, we identified the genes AURKA and AURKB as the strongest hits (those with the highest Z-scores) in all three assays (Fig. 1B and Supplementary Fig. S2). Other genes such as GSG2, SYK, MAPK12, PRKAR2B, and STK22C showed activity in one or two assays, but not in all three. Using Western analysis, we confirmed siRNA depletion of the respective target proteins of our two top hits, Aurora A and Aurora B kinases. Moreover, we observed no obvious differential expression of these proteins in HPV and non-HPV cancer lines (Fig. 1C). With three of the top seven targets (AURKA, AURKB, and GSG2) acting as regulators of mitosis it suggested that mitosis may be the common target in the HPV cancers. However, two mitotic inhibitors, the Plk1 inhibitor, BI-2536 and paclitaxel showed no selectivity between the HPV-positive and -negative cell lines (Supplementary Fig. S3), suggesting a more specific mechanism may be responsible for the HPV-mediated sensitivity.

HPV cancer cell lines are highly sensitive to inhibition of Aurora A kinase in vitro and in vivo

To validate the Aurora kinases as selective targets in HPV-driven cervical cancer, we assessed the activity of well-characterized inhibitors of Aurora A and B. The Aurora B inhibitor ZM447439 (18) was not selective for the HPV lines (Supplementary Fig. S4). The potent, orally active inhibitor of Aurora A kinase, MLN8237/
Alisertib (19) was investigated in a panel of HPV-transformed cervical cancer cell lines. HeLa, CaSki, and ME180 (HPV18/38) were highly sensitive to Alisertib with IC50 values of less than 1 μmol/L, whereas SiHa were less sensitive with an IC50 of 12 μmol/L (Fig. 2A and Supplementary Table S3). The non-HPV cervical cancer cell lines HT3 and C33A were less sensitive with an IC50 value of 2 and 16 μmol/L, respectively (Fig. 2B and Supplementary Table S3). We also tested a panel of squamous cell carcinoma (SCC) cell lines to increase the number of non-HPV cancer cell lines from a keratinocyte origin. These were significantly less sensitive to Alisertib with IC50 values above 5 μmol/L in all cases (Fig. 2C). The difference in drug sensitivity was not a consequence of different proliferative rates, as all cell lines tested had a similar doubling time. The sensitivity of the HPV cervical cancer cell lines are clinically relevant as plasma concentrations of Alisertib on a panel of HPV (A), non-HPV (B), and SCC (C) cancer cell lines using cell viability (resazurin) as the readout. The IC50 values calculated from four replicates are shown.

Figure 2. HPV-transformed cancer cell lines are more sensitive to Alisertib than non-HPV cancer cells. Dose-response curves and IC50 values generated for Alisertib on a panel of HPV (A), non-HPV (B), and SCC (C) cancer cell lines using cell viability (resazurin) as the readout. The IC50 values calculated from four replicates are shown.

To assess the ability of Alisertib to inhibit tumor growth in vivo, nude mice were injected s.c. with either HeLa (HPV16), CaSki (HPV18), or C33A (non-HPV) lines. When tumors had formed and were palpable, Alisertib treatment (orally, 30 mg/kg daily for 10 days) was initiated. The non-HPV C33A tumors showed an initial inhibition of growth that continued to 10 days after the final treatment, but tumor growth recovered to control levels thereafter. By contrast, HeLa and CaSki tumors reached approximately 20 to 35 mm3 during the treatment phase then regressed with Alisertib treatment, with no signs of tumor at day 50 after treatment (Fig. 3A), and excision of the original site of inoculation showed no residual tumor.

We also assessed a transgenic model of HPV16 E7–dependent precancer using a skin graft model. In this model, donor mice have HPV16 E7 expression controlled by the keratin 14 promoter (K14E7) resulting in E7 expression in squamous epithelial keratinocytes, driving hyperplasia of the keratinocytes (21). Grafting of skin from either wild-type or K14E7 mice onto a syngeneic host results in well-healed grafts (22). Mice with well-healed grafts underwent two cycles of 10-day Alisertib treatment, and the mice where then sacrificed and the grafts harvested for immunohistochemical analysis. This treatment resulted in swelling and redening of the K14E7 grafts only. In Alisertib-treated E7 grafts, we observed a significant increase in apoptotic cells compared with untreated E7 grafts (Fig. 3B). No apoptotic cells were detected in the adjacent wild-type grafts. There was also an increase the number of mast cells immediately adjacent to the epidermis in the Alisertib treated E7 grafts compared with both the adjacent wild-type grafts and untreated E7 grafts (Fig. 3C and Supplementary Fig. S5), likely to be in part responsible for the increased swelling of the Alisertib-treated E7 grafts.

Treatment with Alisertib induces polyploidy and cell death in HPV-transformed cervical cancer cell lines.

Cell-cycle progression was analyzed in cells after Alisertib treatment by flow cytometry. Treatment of cells with 5 μmol/L Alisertib for 24 hours resulted in increased cells with 4N and >4N DNA and a reduction in the 2N and S phase population in all cell lines (Fig. 4A; Supplementary Figs. S6 and S7A). There was an increase in the sub-diploid population (<2N) in a time-dependent manner in all cell lines, which was more pronounced in HPV-transformed cells. After 72 hours of treatment, 3 of the 4 HPV-transformed showed high sub-diploid population (HeLa, 70%; Caski and ME180, 75%) indicating cell death. The exception was SiHa, where the sub-diploid population was 36%. By contrast, the two non-HPV cancer cell lines, C33A and HT3, demonstrated lower sub-diploid populations of 14% and 31%, respectively, but accumulated cells with high polyploidy (>4N) suggesting failed cytokinesis, but this did not result in cell death.

To confirm that the induction of 4N and >4N DNA content was a consequence of failure of cytokinesis, all cell lines were subject to immunofluorescence staining of the microtubule cytoskeleton with anti-α-tubulin and DAPI for DNA (Supplementary Fig. S7B). The percentage of binuclear and multinuclear cells 1 and 2 days after Alisertib treatment increased to a similar level in all cells (Supplementary Fig. S7C). Together, these data suggest that the accumulation of cells with 4N or greater DNA content was indeed a consequence of failure of cytokinesis, but only in HPV-transformed cells did this result in a significant loss of viability.

The effects of Alisertib on cell viability were confirmed using time-lapse microscopy. In all cell lines, drug treatment caused cells to arrest in mitosis (rounded mitotic morphology), and undergo failed cytokinesis (producing single daughter cells). However, apoptosis was prominent in the HPV-transformed cell lines (Supplementary Fig. S8). Analysis of the timing of cell death in...
The HPV-transformed cell lines showed that 50% to 60% of cells underwent two rounds of mitosis before triggering cell death quickly, whereas a further 20% required a single mitosis, but then death was delayed for >20 hours (Supplementary Fig. S9). Surprisingly, the length of mitotic arrest induced by the drug was up to 5 times longer in the HPV-transformed lines (Fig. 4B). Aurora A inhibition normally results in a relatively short mitotic delay then exit into failed cytokinesis (23–25). Our data suggest a unique sensitivity in cells where HPV is present that results in a highly extended mitotic arrest.

Mechanism of Alisertib-induced death in HPV cancer cell lines

To examine the apoptosis induced by Alisertib treatment, HeLa cells overexpressing either Bcl-2 or Mcl-1 were assessed for their sensitivity to Alisertib. Etoposide and taxol were used as respective positive controls. The Mcl-1–HeLa cells were highly resistant to Alisertib compared with the parental HeLa, with a >50-fold increase in IC50 (90 nmol/L–4.7 μmol/L). Interestingly, Bcl-2 overexpression had a more modest effect on sensitivity to Alisertib (Fig. 5A). Mcl-1 and Bcl-2 overexpression was protective against taxol and etoposide, respectively (Supplementary Fig. S10), suggesting Alisertib functions via an Mcl-1–sensitive apoptotic mechanism.

A panel of apoptotic components was examined by immunoblotting of the HPV-transformed cervical cancer cell lines after 24, 48, and 72 hours of Alisertib treatment. The level of full-length PARP decreased with a concomitant increase in cleaved PARP in all HPV cell lines tested by 48 hours drug treatment. This was not detected in the non-HPV C33A line (Fig. 5B and Supplementary Fig. S11). The increased PARP cleavage was associated with an increase in the cleavage and activation of caspase-3. The levels of the antiapoptotic Mcl-1, Bcl-2, and Bcl-Xl proteins varied between each cell line. Alisertib treatment had little effect on the levels of Bcl-2 and Bcl-Xl, but there was up to 50% reduction in the level of Mcl-1 in three of the HPV-transformed lines. Alisertib treatment had little effect on either the relatively insensitive SiHa or the non-HPV C33A line. Tumor-suppressor p53 was only readily detectable by immunoblotting in the non-HPV cell lines and was not restored in the HPV-transformed lines by Alisertib treatment. The expression of p53–regulated proapoptotic proteins PUMA, NOXA, and BAD was not affected by Alisertib treatment. An increase in the level of the Mcl-1–selective BIM in the majority of cell lines treated was observed (Fig. 5B and C). The consistently reduced level of Mcl-1 in the Alisertib-treated HPV-transformed cell lines together with the increased level of BIM and the resistance to Alisertib of HeLa cells overexpressing Mcl-1 indicates that the reduced Mcl-1 and increased BIM levels are the mechanism by which apoptosis is induced by Alisertib treatment.

Aurora A inhibition targets host interaction with HPV E7

To determine whether Alisertib sensitivity was a direct consequence of expression of HPV oncogenes, C33A non-HPV cervical cancer and SCC25 non-HPV SCC cell lines were transfected with HPV16 E7 oncogene, then assessed for their sensitivity to Alisertib. Expression of E7 in SCC25 cells (SCC25-HPV16-E7)
resulted in >30-fold reduction of the IC50 value (from >15 to 0.5 μmol/L) whereas E7 expression in C33A cells (C33A-HPV16-E7) resulted in approximately 50% IC50 reduction (Fig. 6A and Supplementary Fig. S12), indicating that E7 expression induces the observed sensitivity. Our previous experiments hint that the level of HPV E7 expression is an important determinant of sensitivity to Alisertib.

Discussion

Here, we have used siRNA kinome screening to identify Aurora A as a molecular target for killing HPV-driven cervical cancer cells. Previously, shRNA-based kinome screens from the Harlow and
Munger laboratories have explored the role of E7 synthetic lethality, but only 100 kinases were screened and these did not include any of our seven top hits (27).

The Aurora A inhibitor, Alisertib, has been used in over 35 clinical trials; however, it has so far only elicited modest responses in range of tumor settings (20, 28, 29). Targeting Aurora A using Alisertib demonstrated selectivity for HPV-transformed cancer cells both in vitro and in vivo. In vitro, the major difference observed was that the HPV cell lines failed cytokinesis and died whereas non-HPV cervical cancer lines failed cytokinesis but remained viable. In xenograft experiments, we observed that non-HPV cervical cancer was somewhat sensitive to Alisertib treatment, showing delayed tumor growth and eventual recovery, a typical response reported for Alisertib in other cancer models (30, 31). By contrast no tumor was detectible in either HeLa or CaSki cells, even 50 days after treatment. Although Alisertib had a more modest effect in mouse K14E7 grafted model, the lack of effect on the adjacent wild-type graft demonstrates the same selectivity observed in the cancer models. The increased apoptosis and mast cell infiltrate point to Alisertib treatment having an HPV-E7-directed effect even in this premalignant setting. Together, these data provide strong evidence that Aurora A selectively targets HPV E7–expressing cells in vitro and in vivo.

This observation is supported by the mechanistic studies, which shows Aurora A depletion/inhibition selectively kills HPV-transformed cervical cancer cell, and this is dependent on HPV E7 expression. The expression HPV E7 in HPV-negative C33A and SCC25 sensitized them to Alisertib and the level of E7 correlated with sensitivity. HPV E7 expression has been reported to increase Aurora A levels (32), though we found little difference in the level of Aurora A in HPV and non-HPV cancer cell lines. HPV E7 can upregulate the expression of the p53-related p73 protein via dysregulated E2F activity, which can transactivate the expression of the proapoptotic proteins PUMA and NOXA. Aurora A has been reported to phosphorylate p73, an HPV E7–regulated gene (33), and inhibit its transcriptional activity, thus inhibiting the expression of p73-regulated PUMA and NOXA-promoting apoptosis (25, 34). However, we found no evidence of this mechanism in Alisertib-dependent death in the HPV-transformed cancer cell lines.

A consistent difference between the Alisertib-treated HPV-transformed and non-HPV cell lines is the time in mitosis, with the HPV-transformed lines all delaying up to five time longer in mitosis as non-HPV cells. These data and the finding that a majority of cells required transit through one or two mitoses before undergoing apoptosis suggested that the extended mitotic delay was a major contributor to the selective killing observed. A number of components of the apoptotic pathway have been reported to be regulated by mitosis. Mcl-1 is destabilized by Cdk1–Cyclin B (35, 36), and BIM, an Mcl-1–selective BH3-only protein (37), is phosphorylated by Aurora A, which promotes its degradation in mitosis. Our data indicate that the apoptosis promoted by Alisertib treatment in the HPV-transformed cells is dependent on Mcl-1. The mechanism by which Aurora A regulates Mcl-1 stability is linked to the increased delay in mitosis found with Aurora A inhibition in the HPV-transformed cells. The longer delay in mitosis increases the destruction of Mcl-1. In addition to this reduction in antiapoptotic signal, inhibition of Aurora A directly stabilizes BIM, increasing proapoptotic signalling. Others have shown that BIM depletion reduced the sensitivity of HeLa cells to Aurora A inhibitor (38), supporting the role for BIM in this...
apoptotic signalling. The combined effect of reduced Mcl-1 and maintenance of BIM levels, which bound by Mcl-1, results in elevated BIM not bound in an antiapoptotic Mcl-1 complex. The degree of Mcl-1 destruction during the mitotic delay may be the factor determining whether one or two mitoses are required for triggering apoptosis, as observed in the time lapse experiments. CDK1–Cyclin B phosphorylation of BCL-2 and Bcl-XL has also been reported to inhibit their antiapoptotic activity (39), and the combined effect of reduction of antiapoptotic Bcl-2, Bcl-XL, and Mcl-1, with maintenance of BIM levels promoting an overall proapoptotic signal.

It may be that the level of E7 expression directly influences CDC20 expression and thereby Mcl-1 stability in mitosis. The level of HPV E7 expression contributes to length of the mitotic delay in Alisertib-treated cells. Low level E7 expression had little effect on time of E7 transduced SCC25 cells in mitosis with Alisertib treatment, but high-level expression in these cells delayed significantly extended the mitotic delay. Only the high-level HPV E7–expressing SCC25 cells showed significant reduction in Mcl-1 levels, consistent with this proposal. The mechanism underlying the effect of Aurora A inhibition in the E7 expressing cells is at present unknown. In summary, we have identified inhibition of Aurora A as a synthetic lethal target in the presence of the HPV E7 oncogene with the small-molecule inhibitor Alisertib selectively and effectively targets HPV E7–expressing cells in vivo. The data presented here demonstrate that targeting Aurora A with drugs such as Alisertib may be an effective therapy for recurrent cervical cancer, and may be useful in treating other HPV-transformed cancer types.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Authors’ Contributions**

Conception and design: B. Gabrielli, F. Bokhari, M.V. Ranall, N.A.J. McMillan


Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): B. Gabrielli, F. Bokhari, M.V. Ranall, A.J. Stevenson, W. Wang, S. McKee, G. Leggatt, P. Leo, H.P. Soyer

Writing, review, and/or revision of the manuscript: B. Gabrielli, F. Bokhari, G. Leggatt, H.P. Soyer, T.J. Gonda, N.A.J. McMillan

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): B. Gabrielli, F. Bokhari, M.V. Ranall, Z.Y. Oo, A.J. Stevenson, W. Wang, S. McKee, D. Skalamera

Study supervision: B. Gabrielli, M.V. Ranall, D. Clarke, D. Skalamera, T.J. Gonda, N.A.J. McMillan

Other (interpretation of data and defining mechanism of action): B. Gabrielli

Other experimental work: S. Fallaha

**Acknowledgments**

The authors thank Takeda Pharmaceuticals for the Alisertib, Associate Professor Nigel Waterhouse and Professor David Huang for their gifts of Mcl-1 expression vector and the Mcl-1-expressing HeLa cells, and Dr. Fiona McMillan and Professor Ian Frazer for their critical reading of the article.

**Grant Support**

This work was supported by grants from the National Health and Medical Research Council (NHMRC) Australia (to B. Gabrielli and N.A.J. McMillan), Australian Cancer Research Fund (to T.J. Gonda), Cancer Council Queensland (to N.A.J. McMillan), Worldwide Cancer Research (formerly Association for International Cancer Research, to B. Gabrielli) and The University of Queensland Diamantina Institute. F. Bokhari was supported by a scholarship from The Medical Service Division, Ministry of Defense, Saudi Arabia. B. Gabrielli is an NHMRC Senior Research Fellow.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received June 17, 2015; revised September 24, 2015; accepted October 4, 2015; published OnlineFirst October 29, 2015.

**References**


Molecular Cancer Therapeutics

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): B. Gabrielli, F. Bokhari, M.V. Ranall, Z.Y. Oo, A.J. Stevenson, W. Wang, M. Murrell, M. Shaikh, M. Kelly, K. Sedeliers, M. Christensen, G. Leggatt, T.J. Gonda

Grant Support

This work was supported by grants from the National Health and Medical Research Council (NHMRC) Australia (to B. Gabrielli and N.A.J. McMillan), Australian Cancer Research Fund (to T.J. Gonda), Cancer Council Queensland (to N.A.J. McMillan), Worldwide Cancer Research (formerly Association for International Cancer Research, to B. Gabrielli) and The University of Queensland Diamantina Institute. F. Bokhari was supported by a scholarship from The Medical Service Division, Ministry of Defense, Saudi Arabia. B. Gabrielli is an NHMRC Senior Research Fellow.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received June 17, 2015; revised September 24, 2015; accepted October 4, 2015; published OnlineFirst October 29, 2015.

**References**


Molecular Cancer Therapeutics

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): B. Gabrielli, F. Bokhari, M.V. Ranall, Z.Y. Oo, A.J. Stevenson, W. Wang, M. Murrell, M. Shaikh, M. Kelly, K. Sedeliers, M. Christensen, G. Leggatt, T.J. Gonda

Grant Support

This work was supported by grants from the National Health and Medical Research Council (NHMRC) Australia (to B. Gabrielli and N.A.J. McMillan), Australian Cancer Research Fund (to T.J. Gonda), Cancer Council Queensland (to N.A.J. McMillan), Worldwide Cancer Research (formerly Association for International Cancer Research, to B. Gabrielli) and The University of Queensland Diamantina Institute. F. Bokhari was supported by a scholarship from The Medical Service Division, Ministry of Defense, Saudi Arabia. B. Gabrielli is an NHMRC Senior Research Fellow.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received June 17, 2015; revised September 24, 2015; accepted October 4, 2015; published OnlineFirst October 29, 2015.

**References**


Molecular Cancer Therapeutics

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): B. Gabrielli, F. Bokhari, M.V. Ranall, Z.Y. Oo, A.J. Stevenson, W. Wang, M. Murrell, M. Shaikh, M. Kelly, K. Sedeliers, M. Christensen, G. Leggatt, T.J. Gonda

Grant Support

This work was supported by grants from the National Health and Medical Research Council (NHMRC) Australia (to B. Gabrielli and N.A.J. McMillan), Australian Cancer Research Fund (to T.J. Gonda), Cancer Council Queensland (to N.A.J. McMillan), Worldwide Cancer Research (formerly Association for International Cancer Research, to B. Gabrielli) and The University of Queensland Diamantina Institute. F. Bokhari was supported by a scholarship from The Medical Service Division, Ministry of Defense, Saudi Arabia. B. Gabrielli is an NHMRC Senior Research Fellow.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received June 17, 2015; revised September 24, 2015; accepted October 4, 2015; published OnlineFirst October 29, 2015.
Aurora A Inhibitor Targets Cervical Cancer


Molecular Cancer Therapeutics

Aurora A Is Critical for Survival in HPV-Transformed Cervical Cancer

Brian Gabrielli, Fawzi Bokhari, Max V. Ranall, et al.

Mol Cancer Ther 2015;14:2753-2761. Published OnlineFirst October 29, 2015.

Updated version
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-15-0506

Supplementary Material
Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2015/10/29/1535-7163.MCT-15-0506.DC1

Cited articles
This article cites 39 articles, 16 of which you can access for free at:
http://mct.aacrjournals.org/content/14/12/2753.full.html#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.